Cargando…

Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization

Bone undergoes constant remodeling of formation by osteoblasts and resorption by osteoclasts. In particular, macrophages have been reported to play an essential role in the regulation of bone homeostasis and regeneration. Naringenin, the predominant flavanone in citrus fruits, is reported to exert a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xin, Zhang, Zheng, Jiang, Weiwei, Hu, Miao, Meng, Yichen, Li, Wenfang, Zhou, Xuhui, Wang, Ce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108355/
https://www.ncbi.nlm.nih.gov/pubmed/35586056
http://dx.doi.org/10.3389/fphar.2022.872188
_version_ 1784708684255854592
author Zhou, Xin
Zhang, Zheng
Jiang, Weiwei
Hu, Miao
Meng, Yichen
Li, Wenfang
Zhou, Xuhui
Wang, Ce
author_facet Zhou, Xin
Zhang, Zheng
Jiang, Weiwei
Hu, Miao
Meng, Yichen
Li, Wenfang
Zhou, Xuhui
Wang, Ce
author_sort Zhou, Xin
collection PubMed
description Bone undergoes constant remodeling of formation by osteoblasts and resorption by osteoclasts. In particular, macrophages have been reported to play an essential role in the regulation of bone homeostasis and regeneration. Naringenin, the predominant flavanone in citrus fruits, is reported to exert anti-inflammatory, anti-osteoclastic, and osteogenic effects. However, whether naringenin could modulate the crosstalk between macrophages and osteoblasts/osteoclasts remains to be investigated. In this study, we confirmed that naringenin enhanced osteogenesis and inhibited osteoclastogenesis directly. Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-β, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-α and IL-1β. In addition, the coculture of primary bone mesenchymal stem cells (BMSCs)/bone marrow monocytes (BMMs) with macrophages showed that the naringenin-treated medium significantly enhanced osteogenic differentiation and impeded osteoclastic differentiation in both inflammatory and non-inflammatory environment. Moreover, in vivo experiments demonstrated that naringenin remarkably reversed LPS-induced bone loss and assisted the healing of calvarial defect. Taken together, naringenin serves as a potential anabolic treatment for pathological bone loss.
format Online
Article
Text
id pubmed-9108355
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91083552022-05-17 Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization Zhou, Xin Zhang, Zheng Jiang, Weiwei Hu, Miao Meng, Yichen Li, Wenfang Zhou, Xuhui Wang, Ce Front Pharmacol Pharmacology Bone undergoes constant remodeling of formation by osteoblasts and resorption by osteoclasts. In particular, macrophages have been reported to play an essential role in the regulation of bone homeostasis and regeneration. Naringenin, the predominant flavanone in citrus fruits, is reported to exert anti-inflammatory, anti-osteoclastic, and osteogenic effects. However, whether naringenin could modulate the crosstalk between macrophages and osteoblasts/osteoclasts remains to be investigated. In this study, we confirmed that naringenin enhanced osteogenesis and inhibited osteoclastogenesis directly. Naringenin promoted M2 transition and the secretion of osteogenic cytokines including IL-4, IL-10, BMP2, and TGF-β, while suppressing LPS-induced M1 polarization and the production of proinflammatory factors such as TNF-α and IL-1β. In addition, the coculture of primary bone mesenchymal stem cells (BMSCs)/bone marrow monocytes (BMMs) with macrophages showed that the naringenin-treated medium significantly enhanced osteogenic differentiation and impeded osteoclastic differentiation in both inflammatory and non-inflammatory environment. Moreover, in vivo experiments demonstrated that naringenin remarkably reversed LPS-induced bone loss and assisted the healing of calvarial defect. Taken together, naringenin serves as a potential anabolic treatment for pathological bone loss. Frontiers Media S.A. 2022-05-02 /pmc/articles/PMC9108355/ /pubmed/35586056 http://dx.doi.org/10.3389/fphar.2022.872188 Text en Copyright © 2022 Zhou, Zhang, Jiang, Hu, Meng, Li, Zhou and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhou, Xin
Zhang, Zheng
Jiang, Weiwei
Hu, Miao
Meng, Yichen
Li, Wenfang
Zhou, Xuhui
Wang, Ce
Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization
title Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization
title_full Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization
title_fullStr Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization
title_full_unstemmed Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization
title_short Naringenin is a Potential Anabolic Treatment for Bone Loss by Modulating Osteogenesis, Osteoclastogenesis, and Macrophage Polarization
title_sort naringenin is a potential anabolic treatment for bone loss by modulating osteogenesis, osteoclastogenesis, and macrophage polarization
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108355/
https://www.ncbi.nlm.nih.gov/pubmed/35586056
http://dx.doi.org/10.3389/fphar.2022.872188
work_keys_str_mv AT zhouxin naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT zhangzheng naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT jiangweiwei naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT humiao naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT mengyichen naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT liwenfang naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT zhouxuhui naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization
AT wangce naringeninisapotentialanabolictreatmentforbonelossbymodulatingosteogenesisosteoclastogenesisandmacrophagepolarization